{"id":2909,"date":"2023-09-25T09:27:56","date_gmt":"2023-09-25T08:27:56","guid":{"rendered":"https:\/\/springerhealthcare.nl\/france\/?p=2909"},"modified":"2023-09-29T09:54:38","modified_gmt":"2023-09-29T08:54:38","slug":"weight-loss-drug-also-protects-against-heart-disease-what-happens-next","status":"publish","type":"post","link":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/","title":{"rendered":"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next?"},"content":{"rendered":"

[vc_row full_width=”stretch_row” content_placement=”middle” css=”.vc_custom_1663187695627{padding-bottom: 37px !important;background-image: url(http:\/\/springerhealthcare.nl\/wp-content\/uploads\/sites\/24\/2022\/09\/science_connect_back.png?id=2486) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}” el_class=”sciencetitle”][vc_column][vc_custom_heading text=”Science Connect” font_container=”tag:h2|text_align:left|color:%23ffffff” use_theme_fonts=”yes” link=”url:https%3A%2F%2Fspringerhealthcare.nl%2Ffrance%2Fscience-connect-september-2023%2F”][vc_column_text css=”.vc_custom_1663186747780{margin-bottom: 40px !important;}”]A Springer Healthcare Initiative For Pharma Professionals<\/span>[\/vc_column_text][vc_column_text]SEPTEMBER 2023
\n<\/span>[\/vc_column_text][\/vc_column][\/vc_row][vc_row css=”.vc_custom_1538651642953{padding-top: 75px !important;}”][vc_column width=”3\/4″ css=”.vc_custom_1538657061395{border-right-width: 1px !important;padding-top: 0px !important;border-right-color: #8faec1 !important;border-right-style: solid !important;}”][vc_custom_heading source=”post_title” font_container=”tag:h1|font_size:40px|text_align:left|line_height:60px” google_fonts=”font_family:Merriweather%3Aregular%2Citalic|font_style:700%20regular%3A700%3Anormal” el_class=”title” css=”.vc_custom_1664358136969{margin-bottom: 30px !important;}”][vc_column_text css=”.vc_custom_1686833173052{padding-bottom: 0px !important;}”]Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashed risk of heart attacks and other cardiovascular incidents in a trial<\/strong><\/span>[\/vc_column_text][vc_column_text el_class=”intro-box”]By Mariana Lenharo<\/span>[\/vc_column_text]

\"weight-loss-drug-also-protects-against-heart-disease-what-happens-next\" <\/div> <\/div>[vc_column_text css=”.vc_custom_1689357004274{margin-bottom: 30px !important;}” el_class=”sc-img-caption”]The injection drugs Wegovy and Ozempic, renowned for their weight loss effects, may also reduce the risk of serious heart problems, a recent trial found. Credit: Carsten Snejbjerg\/Bloomberg via Getty Images[\/vc_column_text][vc_column_text]

Trial results showing that a\u00a0potent anti-obesity drug offers strong protection against serious heart problems<\/a>\u00a0have electrified researchers. They say that the findings could change how this and other members of a\u00a0new generation of obesity drugs<\/a>\u00a0are used, and who receives them.<\/p>\n

The full data from the trial of Wegovy \u2014 a trade name for the drug semaglutide \u2014 have not yet been made public. But results announced by manufacturer Novo Nordisk, headquartered in Bagsv\u00e6rd, Denmark, show that a weekly dose of Wegovy slashed the risk of severe cardiovascular events by 20% in adults with heart disease and either overweight or obesity. The results are the first to suggest that\u00a0semaglutide<\/a>\u00a0protects against serious episodes of cardiovascular disease in people who do not have type 2 diabetes.<\/p>\n

Researchers say the findings, if confirmed, could change the practice of preventive cardiology. The results also suggest that the new generation of anti-obesity drugs can profoundly improve health, not just reduce weight. \u201cThis is probably the most important study in my field in the last ten years,\u201d says Michael Blaha, director of clinical research at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease in Baltimore, Maryland. \u201dIt gets to that cardiometabolic risk that\u2019s been difficult to treat in practice.\u201d<\/p>\n

\u201dIt’s hard to think of other [drugs], apart from statins, that have shown such a profound effect,\u201d says Martha Gulati, director of preventive cardiology at Cedars-Sinai Medical Center in Los Angeles, California.<\/p>\n

WHEN WILL THE FULL DETAILS BE RELEASED?<\/h2>\n

The trial\u2019s full results are expected to be presented at a conference later this year. What\u2019s known so far is that the study, named SELECT, enrolled 17,604 people who already had cardiovascular disease, but no history of diabetes. Participants received injections of either Wegovy or a placebo, and were followed for up to five years. Those who got the drug had a lower risk of heart attack, stroke and death from cardiovascular disease than those who received the placebo.<\/p>\n

WHAT\u2019S DRIVING THE RISK REDUCTION?<\/h2>\n

Semaglutide, which is sold under the names Wegovy for obesity and Ozempic for diabetes, acts by mimicking a hormone called glucagon-like peptide 1 (GLP-1), which is associated with appetite regulation.<\/p>\n

Researchers expected Wegovy to protect against heart disease. Obesity itself is an important risk factor for cardiovascular disease, and weight loss can lead to improvements in other risk factors such as blood pressure and cholesterol levels. But changes in factors other than these might contribute to cutting risk. There\u2019s evidence that drugs that mimic GLP-1 can improve fatty-acid metabolism and reduce inflammation, for example, says Gulati. \u201cThis is what\u2019s so fascinating about these drugs. They work on the brain, the pancreas, the cardiovascular system, the gastrointestinal tract \u2026 There\u2019s more to them than simply weight loss.\u201d<\/p>\n

More data could help to explain whether the protective effect is associated mostly with weight loss or is triggered by other changes promoted by the drug.<\/p>\n

COULD THE NEW OBESITY DRUGS PREVENT OTHER DISEASES?<\/h2>\n

Because obesity is tied to conditions such as hypertension, sleep apnoea and nonalcoholic fatty liver disease, \u201cit is likely that by reducing weight, these comorbid disease conditions will also improve\u201d, says Joseph Wu, the president of the American Heart Association and a cardiologist at the Stanford University School of Medicine in California.<\/p>\n

Blaha notes that the SELECT trial examines a narrow set of severe cardiovascular events and probably underestimates semaglutide\u2019s benefits for cardiovascular health and its potential to enhance mobility, mood and other traits that tend to improve in people who experience weight loss.<\/p>\n

WILL THE RESULTS CHANGE HOW PHYSICIANS PRESCRIBE THE DRUG?<\/h2>\n

Medications such as Wegovy will probably be embraced by a wider range of providers, not only obesity specialists, says Beverly Tchang, an endocrinologist at Weill Cornell Medicine in New York City. She says the results reinforce that Wegovy is a cardiovascular medication as well as a weight-loss drug.<\/p>\n

Wu agrees. \u201cWe will likely see an increase of the drug being prescribed to overweight patients with cardiovascular risk factors,\u201d he says.<\/p>\n

The reframing of Wegovy as a medication for cardiovascular conditions, as opposed to one for obesity, might also improve its acceptability as a long-term drug. \u201cAs a cardiology medication, people will take it more seriously,\u201d Tchang predicts.<\/p>\n

Novo Nordisk expects to apply for approval for more conditions to be treated using Wegovy, both in the United States and in Europe, by the end of the year. The full trial results should provide sufficient evidence for the US Food and Drug Administration to approve the drug for cardiovascular-risk reduction, according to specialists. \u201cWith that label change, I think we\u2019re going to see an even greater prescription of this drug,\u201d Blaha says.<\/p>\n

Cardiologists hope that the SELECT trial\u2019s results will help the drug to become more widely accessible. Some US insurance companies cover the cost of the medication only for people with diabetes. Physicians want to use the new GLP-1-mimicking drugs but hesitate out of fear of \u201cgiving hope to our patients, only [for them] to be turned down by their insurance,\u201d Gulati says. Broader insurance coverage \u201cwill be a game -changer for the clinical practice of preventive cardiology.\u201d<\/p>\n

This article is reproduced with permission and was\u00a0first published<\/a>\u00a0on August 10,\u00a02023.<\/em><\/p>\n[\/vc_column_text][vc_column_text]\u00a9 2023 SCIENTIFIC AMERICAN, A DIVISION OF SPRINGER NATURE AMERICA, INC.[\/vc_column_text][vc_column_text]<\/p>\n

About the Author(s)<\/h3>\n

Mariana Lenharo<\/strong>\u00a0is a life sciences reporter at\u00a0Nature<\/em>. Follow Lenharo on Twitter\u00a0@marilenharo<\/a><\/p>\n[\/vc_column_text][\/vc_column][vc_column width=”1\/4″ css=”.vc_custom_1538657003956{padding-top: 0px !important;padding-bottom: 0px !important;}”][vc_custom_heading text=”ISSUES” font_container=”tag:h3|font_size:12px|text_align:left|color:%23333333|line_height:18px” use_theme_fonts=”yes” el_class=”titlewidget”][vc_column_text el_class=”columnflex” css=”.vc_custom_1664404002021{margin-bottom: 40px !important;}”]

October 2023<\/a><\/p>\r\n

September 2023<\/a><\/p>\r\n

August 2023<\/a><\/p>[\/vc_column_text][vc_custom_heading text=”OTHER ARTICLES IN THIS ISSUE” font_container=”tag:h3|font_size:12px|text_align:left|color:%23333333|line_height:18px” use_theme_fonts=”yes” el_class=”titlewidget” css=”.vc_custom_1674576179369{margin-bottom: 15px !important;}”][vc_basic_grid post_type=”post” max_items=”-1″ style=”load-more” items_per_page=”4″ element_width=”12″ orderby=”rand” item=”538″ grid_id=”vc_gid:1695376300406-57b29906-d9de-3″ taxonomies=”31″][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashed risk of heart attacks and other cardiovascular incidents in a trial. ...more<\/a>","protected":false},"author":29,"featured_media":2910,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[7],"tags":[30,31],"class_list":{"0":"post-2909","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-science-connect","8":"tag-scientific-american","9":"tag-september-2023"},"acf":[],"yoast_head":"\nWeight-Loss Drug Also Protects against Heart Disease. What Happens Next? - SH migration<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next? - SH migration\" \/>\n<meta property=\"og:description\" content=\"Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashed risk of heart attacks and other cardiovascular incidents in a trial.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/\" \/>\n<meta property=\"og:site_name\" content=\"SH migration\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-25T08:27:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-09-29T08:54:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"460\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Lee Kettley\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lee Kettley\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/\"},\"author\":{\"name\":\"Lee Kettley\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/af9de08aa069306e77a209e7ffc24863\"},\"headline\":\"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next?\",\"datePublished\":\"2023-09-25T08:27:56+00:00\",\"dateModified\":\"2023-09-29T08:54:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/\"},\"wordCount\":392,\"image\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp\",\"keywords\":[\"Scientific American\",\"September 2023\"],\"articleSection\":[\"Science Connect\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/\",\"url\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/\",\"name\":\"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next? - SH migration\",\"isPartOf\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp\",\"datePublished\":\"2023-09-25T08:27:56+00:00\",\"dateModified\":\"2023-09-29T08:54:38+00:00\",\"author\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/af9de08aa069306e77a209e7ffc24863\"},\"breadcrumb\":{\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage\",\"url\":\"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp\",\"contentUrl\":\"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp\",\"width\":690,\"height\":460},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/springerhealthplus.nl\/shmigrate\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"aa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/#website\",\"url\":\"https:\/\/springerhealthplus.nl\/shmigrate\/\",\"name\":\"SH migration\",\"description\":\"Acclaimed Content, Global Reach, Diverse Delivery\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/springerhealthplus.nl\/shmigrate\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/af9de08aa069306e77a209e7ffc24863\",\"name\":\"Lee Kettley\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/03dcff2dc955be0ae0163db297d8149d9df34f433a4f50e791447790cc161f0b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/03dcff2dc955be0ae0163db297d8149d9df34f433a4f50e791447790cc161f0b?s=96&d=mm&r=g\",\"caption\":\"Lee Kettley\"},\"url\":\"https:\/\/springerhealthplus.nl\/shmigrate\/author\/lee-kettleyspringer-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next? - SH migration","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"en_US","og_type":"article","og_title":"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next? - SH migration","og_description":"Clinical-trial data suggest that semaglutide, sold under the name Wegovy, slashed risk of heart attacks and other cardiovascular incidents in a trial.","og_url":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/","og_site_name":"SH migration","article_published_time":"2023-09-25T08:27:56+00:00","article_modified_time":"2023-09-29T08:54:38+00:00","og_image":[{"width":690,"height":460,"url":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp","type":"image\/webp"}],"author":"Lee Kettley","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Lee Kettley","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#article","isPartOf":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/"},"author":{"name":"Lee Kettley","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/af9de08aa069306e77a209e7ffc24863"},"headline":"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next?","datePublished":"2023-09-25T08:27:56+00:00","dateModified":"2023-09-29T08:54:38+00:00","mainEntityOfPage":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/"},"wordCount":392,"image":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage"},"thumbnailUrl":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp","keywords":["Scientific American","September 2023"],"articleSection":["Science Connect"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/","url":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/","name":"Weight-Loss Drug Also Protects against Heart Disease. What Happens Next? - SH migration","isPartOf":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/#website"},"primaryImageOfPage":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage"},"image":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage"},"thumbnailUrl":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp","datePublished":"2023-09-25T08:27:56+00:00","dateModified":"2023-09-29T08:54:38+00:00","author":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/af9de08aa069306e77a209e7ffc24863"},"breadcrumb":{"@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#primaryimage","url":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp","contentUrl":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-content\/uploads\/sites\/24\/2023\/09\/A4D6E39C-86F7-4BB2-B6BDFC99D4C6879B_source.webp","width":690,"height":460},{"@type":"BreadcrumbList","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/weight-loss-drug-also-protects-against-heart-disease-what-happens-next\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/springerhealthplus.nl\/shmigrate\/"},{"@type":"ListItem","position":2,"name":"aa"}]},{"@type":"WebSite","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/#website","url":"https:\/\/springerhealthplus.nl\/shmigrate\/","name":"SH migration","description":"Acclaimed Content, Global Reach, Diverse Delivery","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/springerhealthplus.nl\/shmigrate\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/af9de08aa069306e77a209e7ffc24863","name":"Lee Kettley","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/springerhealthplus.nl\/shmigrate\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/03dcff2dc955be0ae0163db297d8149d9df34f433a4f50e791447790cc161f0b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/03dcff2dc955be0ae0163db297d8149d9df34f433a4f50e791447790cc161f0b?s=96&d=mm&r=g","caption":"Lee Kettley"},"url":"https:\/\/springerhealthplus.nl\/shmigrate\/author\/lee-kettleyspringer-com\/"}]}},"menu_order":0,"_links":{"self":[{"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/posts\/2909","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/comments?post=2909"}],"version-history":[{"count":0,"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/posts\/2909\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/media\/2910"}],"wp:attachment":[{"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/media?parent=2909"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/categories?post=2909"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/springerhealthplus.nl\/shmigrate\/wp-json\/wp\/v2\/tags?post=2909"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}